Monopar Therapeutics
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | — | — | — |
| Research and development | $9.9M | $13.0M | $5.6M | $7.6M | $6.5M |
| Operating expenses | $16.7M | $16.2M | $8.8M | $10.5M | $9.1M |
| Operating income | -$16.7M | -$16.2M | -$8.8M | -$10.5M | -$9.1M |
| Pretax income | -$13.7M | -$15.6M | -$8.4M | — | — |
| Income tax expense | $800 | $800 | $800 | $800 | $0 |
| Net income | -$13.7M | -$15.6M | -$8.4M | -$10.5M | -$9.1M |
| Balance Sheet | |||||
| Cash and equivalents | $61.8M | $45.8M | $7.3M | $8.2M | $20.3M |
| Current assets | $140.5M | $60.3M | $7.3M | $13.2M | $20.5M |
| Total assets | $140.7M | $60.3M | $7.3M | $13.2M | $20.5M |
| Current liabilities | $2.7M | $5.3M | $1.8M | $3.1M | $1.6M |
| Total liabilities | $2.9M | $5.3M | $1.8M | $3.1M | $1.6M |
| Stockholders' equity | $137.8M | $55.0M | $5.6M | $10.1M | $18.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$12.2M | -$6.4M | -$7.9M | -$7.2M | -$7.3M |
| Stock-based compensation | $4.8M | $1.1M | $1.9M | $1.6M | $1.5M |
| Share repurchases | $35.0M | $0 | — | — | — |
Shares outstanding 6.7M · Free float 68.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.